Mechanisms of chromate carcinogenesis by chromatin alterations.

Q1 Pharmacology, Toxicology and Pharmaceutics Advances in pharmacology Pub Date : 2023-01-01 DOI:10.1016/bs.apha.2022.07.001
Hesbon A Zablon, Andrew VonHandorf, Alvaro Puga
{"title":"Mechanisms of chromate carcinogenesis by chromatin alterations.","authors":"Hesbon A Zablon,&nbsp;Andrew VonHandorf,&nbsp;Alvaro Puga","doi":"10.1016/bs.apha.2022.07.001","DOIUrl":null,"url":null,"abstract":"<p><p>In a dynamic environment, organisms must constantly mount an adaptive response to new environmental conditions in order to survive. Novel patterns of gene expression, driven by attendant changes in chromatin architecture, aid in adaptation and survival. Critical mechanisms in the control of gene transcription govern new spatiotemporal chromatin-chromatin interactions that make regulatory DNA elements accessible to the transcription factors that control the response. Consequently, agents that disrupt chromatin structure are likely to have a direct impact on the transcriptional programs of cells and organisms and to drive alterations in fundamental physiological processes. In this regard, hexavalent chromium (Cr(VI)) is of special interest because it interacts directly with cellular proteins, DNA, and other macromolecules, and is likely to upset cell functions that may cause generalized damage to the organism. Here, we will highlight chromium-mediated mechanisms that disrupt chromatin architecture and discuss how these mechanisms are integral to its carcinogenic properties. Emerging evidence indicates that Cr(VI) targets euchromatin, particularly in genomic locations flanking the binding sites of the essential transcription factors CTCF and AP1, and, in so doing, they disrupt nucleosomal architecture. Ultimately, the ensuing changes, if occurring in critical regulatory domains, may establish a new chromatin state, either toxic or adaptive, that will be governed by the corresponding gene transcription changes in key biological processes associated with that state.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"96 ","pages":"1-23"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.apha.2022.07.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

In a dynamic environment, organisms must constantly mount an adaptive response to new environmental conditions in order to survive. Novel patterns of gene expression, driven by attendant changes in chromatin architecture, aid in adaptation and survival. Critical mechanisms in the control of gene transcription govern new spatiotemporal chromatin-chromatin interactions that make regulatory DNA elements accessible to the transcription factors that control the response. Consequently, agents that disrupt chromatin structure are likely to have a direct impact on the transcriptional programs of cells and organisms and to drive alterations in fundamental physiological processes. In this regard, hexavalent chromium (Cr(VI)) is of special interest because it interacts directly with cellular proteins, DNA, and other macromolecules, and is likely to upset cell functions that may cause generalized damage to the organism. Here, we will highlight chromium-mediated mechanisms that disrupt chromatin architecture and discuss how these mechanisms are integral to its carcinogenic properties. Emerging evidence indicates that Cr(VI) targets euchromatin, particularly in genomic locations flanking the binding sites of the essential transcription factors CTCF and AP1, and, in so doing, they disrupt nucleosomal architecture. Ultimately, the ensuing changes, if occurring in critical regulatory domains, may establish a new chromatin state, either toxic or adaptive, that will be governed by the corresponding gene transcription changes in key biological processes associated with that state.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
染色质改变致铬酸盐癌的机制。
在动态环境中,生物必须不断地对新的环境条件做出适应性反应才能生存。在染色质结构变化的驱动下,新的基因表达模式有助于适应和生存。基因转录控制的关键机制控制新的时空染色质相互作用,使调控DNA元件接近控制反应的转录因子。因此,破坏染色质结构的药物可能对细胞和生物体的转录程序产生直接影响,并驱动基本生理过程的改变。在这方面,六价铬(Cr(VI))是特别感兴趣的,因为它直接与细胞蛋白质,DNA和其他大分子相互作用,并且可能扰乱细胞功能,从而可能对生物体造成广泛的损害。在这里,我们将强调铬介导的破坏染色质结构的机制,并讨论这些机制如何与其致癌特性相结合。新出现的证据表明,Cr(VI)靶向常染色质,特别是在必需转录因子CTCF和AP1结合位点两侧的基因组位置,并且在这样做时,它们破坏核小体结构。最终,如果发生在关键调控区域,随后的变化可能会建立一种新的染色质状态,可能是有毒的,也可能是适应性的,这种状态将由与该状态相关的关键生物学过程中相应的基因转录变化所控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Advances in pharmacology
Advances in pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
9.10
自引率
0.00%
发文量
45
期刊最新文献
Drug discovery strategy for TAK-418, a specific inhibitor of LSD1 enzyme activity, as a novel therapy for autism. Evolution of D-amino acid oxidase inhibitors: From concept to clinic. Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function. Modulatory and protective effects of prolyl hydroxylase domain inhibitors in the central nervous system. Neutral sphingomyelinase 2: A promising drug target for CNS disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1